Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T, Okubo Y, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Uehara N, Handa T, Tanaka M, Zhang W, Paris M, Murakami M. Terui T, et al. Among authors: okubo y. Am J Clin Dermatol. 2024 Jan;25(1):165-167. doi: 10.1007/s40257-023-00825-0. Am J Clin Dermatol. 2024. PMID: 38060175 Free PMC article. No abstract available.
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O. Ohtsuki M, et al. Among authors: okubo y. J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9. J Dermatol. 2017. PMID: 28391657 Free PMC article. Clinical Trial.
Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.
Kanekura T, Seishima M, Honma M, Etou T, Eto H, Okuma K, Okubo Y, Yamaguchi Y, Kambara T, Mabuchi T, Suga Y, Morita A, Yamanishi K, Tsuruta D, Itoh K, Yamaji K, Ikeda S. Kanekura T, et al. Among authors: okubo y. J Dermatol. 2017 Dec;44(12):1353-1359. doi: 10.1111/1346-8138.13975. Epub 2017 Aug 3. J Dermatol. 2017. PMID: 28771892 Clinical Trial.
Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A, Takahashi H, Ozawa K, Imafuku S, Nakama T, Takahashi K, Matsuyama T, Okubo Y, Kitamura S, Matsuda N, Zhao Y, Yokoyama M, Hayashi N, Terui T. Morita A, et al. Among authors: okubo y. J Dermatol. 2019 Sep;46(9):745-751. doi: 10.1111/1346-8138.14997. Epub 2019 Jul 8. J Dermatol. 2019. PMID: 31282051 Free PMC article. Clinical Trial.
1,411 results